Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5172 with peginterferon alfa-2b and ribavirin in treatment-naive chronic hepatitis C genotype 2 or 3
2011-003299-36Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of grazoprevir in hepatitis C virus infection, sponsored by Merck & Co.. Started Mar 2012; status: terminated.
02
Drugs
grazoprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2011-003299-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003299-36.